Rhythm Pharmaceuticals (DE:1RV)
NASDAQ:1RV
1RV Stock Chart & Stats
€72.00
€1.00(1.77%)
At close: 4:00 PM EST
€72.00
€1.00(1.77%)
Day’s Range― - ―
52-Week Range€52.00 - €99.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.20B
Enterprise Value€6.22B
Total Cash (Recent Filing)€340.63M
Total Debt (Recent Filing)€227.02M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 04, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding68,593,575
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€118.26Price Target Upside64.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.68
Revenue Forecast (FY)€253.44M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling And High Gross MarginsThe company has demonstrated durable top-line expansion and very high gross margins, indicating attractive unit economics and scalable product margins. Over a 2–6 month horizon this supports funding commercial expansion and absorbing incremental SG&A while preserving strong gross profit per patient.
Expanding Regulatory Footprint (U.S. FDA Approval)Securing the first FDA approval for acquired hypothalamic obesity materially increases the addressable patient population and reinforces market leadership in precision obesity. This structural approval supports sustainable recurring revenue and strengthens negotiating leverage with payers across markets.
Solid Liquidity And RunwayA multi-year cash runway reduces near-term financing pressure and allows management to invest in commercialization, payer access, and clinical programs. Over the medium term this enables execution on launches and trials without immediate dilution or debt raises, supporting strategic continuity.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained cash outflows from operations mean the business relies on external financing to fund growth and trials. This structural burn constrains flexibility, increases vulnerability to financing market conditions, and can force tradeoffs between commercialization investment and R&D over the next several quarters.
Rising Leverage And Shrinking EquityElevated leverage and declining equity reduce balance-sheet flexibility and raise refinancing or covenant risk. Over a 2–6 month horizon this limits capacity for opportunistic M&A or large upfront commercial investments and increases the chance of dilutive funding or cost-of-capital pressure.
Phase 3 EMANATE Missed Primary EndpointsFailure to meet primary endpoints in expansion Phase 3 studies weakens prospects for broad label expansion and heightens development risk. Structurally this necessitates refined patient selection, additional trials or pivoted programs, slowing revenue diversification beyond current approved indications.
Rhythm Pharmaceuticals News
1RV FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was €52.00 and its highest was €99.00 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is €5.20B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 52 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on May 05, 2026. The company reported -€0.712 earnings per share for the quarter, missing the consensus estimate of -€0.705 by -€0.007.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.7.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 68,593,575 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -€0.712 in its last earnings report, missing expectations of -€0.705. Following the earnings report the stock price went up 8.209%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1RV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€118.26 (64.25% Upside)
€118.26 (64.25% Upside)
Blogger Sentiment
Bullish
DE:1RV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €369.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.19%
12-Months-Change
Fundamentals
Return on Equity
-203.25%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
1RV Company Deck
1RV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.View all DE:1RV earnings summaries1RV Stock 12 Month Forecast
Average Price Target
€118.26
▲(64.25% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Options Prices
Currently, No data available
---